Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

Travere Therapeutics, Inc. (RTRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Heerma Peter (Chief Commercial Officer) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 3,091 shares @ $8.2511, valued at $25.5k
05/19/2023 4 Baynes Roy D. (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Poole Sandra (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 COUGHLIN TIMOTHY (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Williams Brinkley Ruth (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Meckler Jeffrey A (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Orwin John A (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 LYONS GARY A (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Bruhn Suzanne Louise (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/19/2023 4 Squarer Ron (Director) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 4,500 shares @ $0
Granted 13,500 options to buy @ $17.11, valued at $231k
05/12/2023 4 Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 455 shares @ $16.59, valued at $7.5k
05/12/2023 4 REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 825 shares @ $16.59, valued at $13.7k
04/13/2023 4 Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 47 shares @ $21.49, valued at $1k
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/26/2023 4 Calvin Sandra (SVP, Chief Accounting Officer) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 905 shares @ $21.9044, valued at $19.8k
Sold 192 shares @ $21.63, valued at $4.2k
01/26/2023 4 ROTE WILLIAM E. (Senior Vice President, R&D) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 2,062 shares @ $21.5, valued at $44.3k
01/26/2023 4 REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 2,062 shares @ $21.5, valued at $44.3k
01/26/2023 4 Dube Eric M (CEO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 6,442 shares @ $21.5, valued at $138.5k
01/26/2023 4 Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 852 shares @ $21.9044, valued at $18.7k
01/26/2023 4 Heerma Peter (Chief Commercial Officer) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 1,550 shares @ $21.9044, valued at $34k
01/06/2023 4 Dube Eric M (CEO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 5,625 shares @ $20.75, valued at $116.7k
01/06/2023 4 Inrig Jula (Chief Medical Officer) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 2,051 shares @ $20.75, valued at $42.6k
Sold 442 shares @ $20.75, valued at $9.2k
10/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/15/2022 4 Calvin Sandra (SVP, Chief Accounting Officer) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 349 shares @ $28, valued at $9.8k
09/01/2022 4 Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Granted 5,000 shares @ $0
Granted 48,000 options to buy @ $28.06, valued at $1.3M
Granted 9,840 options to buy @ $0
09/01/2022 3 Cline Christopher R. (CFO) has filed a Form 3 on Travere Therapeutics, Inc.
05/12/2022 4 ROTE WILLIAM E. (Senior Vice President, R&D) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 750 shares @ $21.93, valued at $16.4k
Sold 813 shares @ $21.5163, valued at $17.5k
05/12/2022 4 REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.
Txns: Sold 900 shares @ $21.51, valued at $19.4k
Sold 1,050 shares @ $21.509, valued at $22.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy